(MedPage Today) — Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of 26,000 patients showed.
Overall, 35% of patients’ records had evidence of comprehensive genomic profiling…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116476
Author :
Publish date : 2025-07-11 21:01:00
Copyright for syndicated content belongs to the linked Source.
